Related Experiment Video
Updated: May 25, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Warfarin versus dabigatran: comparing the old with the new
Mary Elizabeth Abraham1, Todd R Marcy
1University of Oklahoma College of Pharmacy, Oklahoma City, OK, USA.
Summary
Warfarin and dabigatran are effective anticoagulants for preventing blood clots, with comparable safety profiles. Patient-specific factors and informed choices are crucial for selecting the most suitable oral anticoagulant.
Area of Science:
- Pharmacology
- Cardiology
- Internal Medicine
Background:
- Warfarin, an oral anticoagulant, necessitates regular monitoring and lifestyle adherence for managing thromboembolism.
- Dabigatran, a direct thrombin inhibitor, is approved for stroke prevention in atrial fibrillation, offering advantages like no required monitoring.
Purpose of the Study:
- To compare the efficacy and safety of warfarin and dabigatran.
- To discuss the advantages and disadvantages of each anticoagulant.
- To highlight the importance of patient-specific decision-making in anticoagulant therapy.
Main Methods:
- Review of clinical studies comparing warfarin and dabigatran.
- Analysis of factors influencing anticoagulant effects.
- Examination of consensus guideline recommendations.
Main Results:
- Both warfarin and dabigatran demonstrate comparable effectiveness in clinical studies.
- Major bleeding rates were similar between the two anticoagulant agents.
- Dabigatran offers convenience due to lack of monitoring but has potential gastrointestinal side effects and higher cost.
Conclusions:
- Selecting an oral anticoagulant requires a patient-specific approach.
- Informed patient perspectives are essential for optimizing anticoagulant therapy.
- Guidelines offer divergent recommendations, underscoring the need for individualized treatment plans.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...